Header Logo

HOMER A MACAPINLAC

TitleProfessor
InstitutionMD Anderson
DepartmentNuclear Medicine
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784. PMID: 38238616; PMCID: PMC10957466.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    2. Kairemo K, Gouda MA, Buschhorn L, Wahida A, Macapinlac HA, Anderson PM, Subbiah V. Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open. 2023 08; 8(4):101575. PMID: 37517365; PMCID: PMC10400850.
      Citations:    Translation:Humans
    3. Kairemo K, Kangasm?ki A, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis. Life (Basel). 2022 Nov 25; 12(12). PMID: 36556342; PMCID: PMC9788581.
      Citations: 1     
    4. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44. PMID: 36068929; PMCID: PMC9771924.
      Citations:    
    5. Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma. Clin Nucl Med. 2022 Mar 01; 47(3):209-218. PMID: 35020640; PMCID: PMC8851692.
      Citations: 1     Fields:    Translation:Humans
    6. Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2022 03; 4(2):e210091. PMID: 35212559; PMCID: PMC8965534.
      Citations:    Fields:    Translation:Humans
    7. Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181. PMID: 35068861; PMCID: PMC8704272.
      Citations:    Fields:    Translation:Humans
    8. Lu Y, Sweiss NJ, Macapinlac HA. What Is the Optimal Method on Myocardial Suppression in FDG PET/CT Evaluation of Cardiac Sarcoidosis? Clin Nucl Med. 2021 Nov 01; 46(11):904-905. PMID: 34132675.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Kairemo K, Jessop AC, Vija AH, Ding X, Spence D, Kappadath SC, Macapinlac HA. A Prospective Comparative Study of Using Ultrasonography, 4D-CT and Parathyroid Dual-Phase Scintigraphy with SPECT in Patients with Primary Hyperparathyroidism. Diagnostics (Basel). 2021 Oct 28; 11(11). PMID: 34829354; PMCID: PMC8618687.
      Citations:    
    10. Lin M, Paolillo V, Le DB, Macapinlac H, Ravizzini GC. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer. 2021 10; 45(5):100796. PMID: 34657748.
      Citations:    Fields:    Translation:Humans
    11. Kairemo K, Roszik J, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer. 2021 10; 45(5):100797. PMID: 34706830.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 01; 63(1):74-83. PMID: 34435552; PMCID: PMC9284943.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Zhou Z, Jain P, Lu Y, Macapinlac H, Wang ML, Son JB, Pagel MD, Xu G, Ma J. Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network. Am J Nucl Med Mol Imaging. 2021; 11(4):260-270. PMID: 34513279; PMCID: PMC8414404.
      Citations: 2     
    14. Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun. 2021 Jul 01; 42(7):755-762. PMID: 33741867.
      Citations:    Fields:    Translation:Humans
    15. Minamimoto R, Fayad L, Vose J, Meza J, Advani R, Hankins J, Mottaghy F, Macapinlac H, Heinzel A, Juweid ME, Quon A. 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2021 08; 48(9):2883-2893. PMID: 33909086; PMCID: PMC8263539.
      Citations: 1     Fields:    Translation:Humans
    16. Teyateeti A, Teyateeti A, Ravizzini GC, Xu G, Tang C, Tu SM, Macapinlac HA, Lu Y. Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level = 0.5 ng/ml after multiple treatment failures. Am J Nucl Med Mol Imaging. 2021; 11(2):87-98. PMID: 34079638; PMCID: PMC8165728.
      Citations: 1     
    17. Kairemo K, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis. Diagnostics (Basel). 2020 Dec 24; 11(1). PMID: 33374148; PMCID: PMC7824105.
      Citations: 2     
    18. Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131. PMID: 32984089; PMCID: PMC7500841.
      Citations: 4     
    19. Teyateeti A, Teyateeti A, Macapinlac HA, Lu Y. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment? Clin Nucl Med. 2020 Sep; 45(9):672-678. PMID: 32604105.
      Citations: 2     Fields:    Translation:Humans
    20. Teyateeti A, Khan B, Teyateeti A, Chen B, Bridhikitti J, Pan T, Peng W, Macapinlac HA, Lu Y. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level =0.5?ng/mL. Nucl Med Commun. 2020 Sep; 41(9):906-915. PMID: 32796479.
      Citations: 3     Fields:    Translation:Humans
    21. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020 11 15; 26(22):5830-5842. PMID: 32816889.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    22. Lu Y, Macapinlac HA. Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic. Eur J Nucl Med Mol Imaging. 2020 08; 47(9):2064-2065. PMID: 32383092; PMCID: PMC7205478.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    23. Lu Y, Yan SX, Lan X, Zhu X, Macapinlac HA. Nuclear medicine in responding to global pandemic COVID-19-American College of Nuclear Medicine member experience. Eur J Nucl Med Mol Imaging. 2020 07; 47(7):1620-1622. PMID: 32296884; PMCID: PMC7158754.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    24. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020 May; 45(5):349-355. PMID: 31977495.
      Citations:    Fields:    Translation:Humans
    25. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel). 2020 Feb 25; 10(3). PMID: 32106426; PMCID: PMC7151088.
      Citations: 1     
    26. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553. PMID: 32023374; PMCID: PMC7101242.
      Citations: 479     Fields:    Translation:HumansCellsCTClinical Trials
    27. Kairemo K, Santos EB, Macapinlac HA, Subbiah V. Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. Diagnostics (Basel). 2020 Jan 06; 10(1). PMID: 31935818; PMCID: PMC7169847.
      Citations: 4     
    28. Chen B, Wei P, Macapinlac HA, Lu Y. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nucl Med Commun. 2019 Sep; 40(9):940-946. PMID: 31343613.
      Citations: 10     Fields:    Translation:Humans
    29. Vija AH, Froelich JW, Macapinlac H, Daignault CP, Gowda N, Hadjiev O, Hephzibah J, Huang P, Jessop A, Cachovan M, Ma J, Ding X, Spence D, Platsch G, Szabo Z, Bartenstein PA, Kuwert T, Ilhan H. ROC study and SUV threshold using quantitative multi-modal SPECT for bone imaging. Eur J Hybrid Imaging. 2019 Jun 28; 3(1):10. PMID: 34191147; PMCID: PMC8218047.
      Citations: 2     
    30. Dai D, Chuang HH, Macapinlac HA, Li T, Pan T. Correlation of fluorine 18-labeled sodium fluoride uptake and arterial calcification on whole-body PET/CT in cancer patients. Nucl Med Commun. 2019 Jun; 40(6):604-610. PMID: 30688757.
      Citations: 1     Fields:    Translation:Humans
    31. Chen B, Macapinlac HA, Lu Y. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases. Clin Nucl Med. 2019 Apr; 44(4):337-338. PMID: 30688749.
      Citations: 2     Fields:    Translation:Humans
    32. Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open. 2019; 4(1):e000439. PMID: 30962954; PMCID: PMC6435244.
      Citations: 7     
    33. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810. PMID: 30733229; PMCID: PMC6606382.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    34. Lu Y, Sweiss NJ, Macapinlac HA. Prognostic Impact of FDG-PET/CT Images?in Patients With Suspected?Cardiac?Sarcoidosis: Optimal Patient Preparation, Not Complex Unconventional?Analytics, Is Key to Meaningful Data. JACC Cardiovasc Imaging. 2019 01; 12(1):217-219. PMID: 30621993.
      Citations: 1     Fields:    Translation:Humans
    35. Etchebehere E, Kairemo K, Rohren E, Araujo J, Macapinlac H, Brito AE. Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy? Radiol Bras. 2019 Jan-Feb; 52(1):33-40. PMID: 30804613; PMCID: PMC6383535.
      Citations: 3     
    36. Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 12; 45(13):2256-2263. PMID: 29785515.
      Citations: 10     Fields:    Translation:Humans
    37. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311. PMID: 29476021; PMCID: PMC5955837.
      Citations: 2     Fields:    Translation:Humans
    38. Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Curr Radiopharm. 2018; 11(2):147-152. PMID: 29956640.
      Citations: 4     Fields:    Translation:Humans
    39. Lu Y, Chasen BA, Macapinlac HA. Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease. Clin Nucl Med. 2017 Dec; 42(12):980-982. PMID: 29076903.
      Citations:    Fields:    Translation:Humans
    40. Chism CB, Ravizzini GC, Macapinlac HA, Pan T. Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions. Nucl Med Commun. 2017 Jun; 38(6):529-536. PMID: 28383318.
      Citations:    Fields:    Translation:Humans
    41. Rohren EM, Macapinlac HA. Spectrum of Benign Bone Conditions on NaF-PET. Semin Nucl Med. 2017 07; 47(4):392-396. PMID: 28583278.
      Citations: 2     Fields:    Translation:Humans
    42. Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah V. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel). 2017 Apr 04; 7(2). PMID: 28375169; PMCID: PMC5489940.
      Citations: 2     
    43. Erwin WD, Jessop AC, Mar MV, Macapinlac HA, Mawlawi OR. Qualitative and quantitative comparison of gated blood pool single photon emission computed tomography using low-energy high-resolution and SMARTZOOM collimation. Nucl Med Commun. 2017 Jan; 38(1):35-43. PMID: 27775993.
      Citations:    Fields:    Translation:Humans
    44. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978. PMID: 27942837; PMCID: PMC5400685.
      Citations: 5     Fields:    Translation:HumansCells
    45. Etchebehere EC, Fox P, Macapinlac H, Rohren E, Milton D. Reply: Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data. J Nucl Med. 2016 06; 57(6):991. PMID: 27081171.
      Citations:    Fields:    
    46. Araujo JC, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM, Etchebehere EC, Milton DR. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73. PMID: 26828141.
      Citations: 7     Fields:    Translation:Humans
    47. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology. 2016 07; 280(1):220-9. PMID: 26854705; PMCID: PMC4934532.
      Citations: 16     Fields:    Translation:Humans
    48. Etchebehere EC, Hobbs BP, Malawi O, Patel S, Benjamin RS, Macapinlac HA, Milton DR. Assessing the role of ?8F-FDG PET and ?8F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016 May; 43(5):860-870. PMID: 26631240; PMCID: PMC5048410.
      Citations: 9     Fields:    Translation:Humans
    49. Etchebehere EC, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM, Milton DR. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016 Jan; 43(1):8-20. PMID: 26416392.
      Citations: 21     Fields:    Translation:Humans
    50. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501; PMCID: PMC4663130.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    51. Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12. PMID: 26135112; PMCID: PMC5025941.
      Citations: 31     Fields:    Translation:Humans
    52. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84. PMID: 26069307.
      Citations: 48     Fields:    Translation:Humans
    53. Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL, Cuellar SL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
      Citations: 15     Fields:    Translation:Humans
    54. Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL, Macapinlac HA, Chuang HH. Impact of ?8F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014 Nov; 41(11):2066-73. PMID: 24990404.
      Citations: 12     Fields:    Translation:Humans
    55. Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH. The value of ?8F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. 2014 Sep; 41(9):1756-66. PMID: 24699907.
      Citations: 6     Fields:    Translation:HumansCells
    56. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol. 2014 Apr; 133(1):100-4. PMID: 24534359; PMCID: PMC4000233.
      Citations: 7     Fields:    Translation:Humans
    57. Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL, Macapinlac HA. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14. PMID: 24442598.
      Citations: 16     Fields:    Translation:Humans
    58. Bhosale P, Balachandran A, Vikram R, Viswanathan C, Macapinlac H, Rohren E, Prativadi R. What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies? Int J Mol Imaging. 2013; 2013:476786. PMID: 24455242; PMCID: PMC3888763.
      Citations: 4     
    59. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013 Oct 20; 31(30):3823-30. PMID: 24043740; PMCID: PMC3795891.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    60. Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT. Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. 2014 Jan-Feb; 21(1):3-8. PMID: 23911560; PMCID: PMC4283493.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    61. Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7. PMID: 22810967; PMCID: PMC4283482.
      Citations: 4     Fields:    Translation:Humans
    62. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642. PMID: 22831985; PMCID: PMC3457750.
      Citations: 27     Fields:    Translation:Humans
    63. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. Comparative study of the value of dual tracer PET/CT in evaluating breast cancer. Cancer Sci. 2012 Sep; 103(9):1701-7. PMID: 22632272; PMCID: PMC7659263.
      Citations: 3     Fields:    Translation:Humans
    64. Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med. 2012 Jul; 42(4):255-60. PMID: 22681674.
      Citations: 6     Fields:    Translation:HumansAnimals
    65. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8. PMID: 22586182; PMCID: PMC4347306.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    66. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology. 2012 Apr; 263(1):53-63. PMID: 22438441.
      Citations: 54     Fields:    Translation:Humans
    67. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    68. Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM. Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality. J Nucl Med Technol. 2011 Jun; 39(2):83-90. PMID: 21565950.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    69. Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac H, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG. Evaluation of ?8F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol. 2011 Oct; 18(10):2783-9. PMID: 21476107.
      Citations: 10     Fields:    Translation:Humans
    70. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33. PMID: 21456015; PMCID: PMC3144261.
      Citations: 28     Fields:    Translation:Humans
    71. Macapinlac HA, Czernin J, Larson SM. Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol. 2011 Feb; 13(1):1-2. PMID: 21082268.
      Citations:    Fields:    Translation:Humans
    72. Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE, Dickinson RL. Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies. Int J Mol Imaging. 2011; 2011:298102. PMID: 21490727; PMCID: PMC3065894.
      Citations: 2     
    73. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34. PMID: 21509770; PMCID: PMC4286384.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    74. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94. PMID: 20629031.
      Citations: 6     Fields:    Translation:Humans
    75. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      Citations: 12     Fields:    Translation:Humans
    76. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
      Citations: 10     Fields:    Translation:Humans
    77. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44. PMID: 20683399.
      Citations: 13     Fields:    Translation:Humans
    78. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8. PMID: 20660382.
      Citations: 22     Fields:    Translation:HumansCells
    79. Bacher U, Bader P, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS, Kr?ger N, B?ttcher S. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. PMID: 20558311; PMCID: PMC7272718.
      Citations: 29     Fields:    Translation:Humans
    80. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol. 2010 May; 194(5):W401-6. PMID: 20410385.
      Citations: 22     Fields:    Translation:Humans
    81. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74. PMID: 20171802; PMCID: PMC3072063.
      Citations: 11     Fields:    Translation:HumansCells
    82. Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys. 2010 Feb 04; 11(1):3073. PMID: 20160693; PMCID: PMC3883558.
      Citations:    Fields:    Translation:Humans
    83. Erwin WD, Wendt RE, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA, N??ez R. Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner. Mol Imaging Biol. 2010 Apr; 12(2):110-38. PMID: 20049543.
      Citations: 3     Fields:    Translation:Humans
    84. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
      Citations: 24     Fields:    Translation:Humans
    85. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9. PMID: 19602564.
      Citations: 31     Fields:    Translation:HumansCells
    86. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009 Jun; 7 Suppl 2:S1-26. PMID: 19555588.
      Citations: 25     Fields:    Translation:Humans
    87. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11. PMID: 19451443.
      Citations: 46     Fields:    Translation:HumansCells
    88. Schechter NR, Erwin WD, Yang DJ, Kim EE, Munden RF, Forster K, Taing LC, Cox JD, Macapinlac HA, Podoloff DA. Radiation dosimetry and biodistribution of (99m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2009 Oct; 36(10):1583-91. PMID: 19396440; PMCID: PMC2758190.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    89. Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imaging. 2009 Apr; 53(2):201-9. PMID: 19293768.
      Citations: 3     Fields:    Translation:Humans
    90. Rohren EM, Macapinlac HA. PET Imaging of Prostate Cancer: Other Tracers. PET Clin. 2009 Apr; 4(2):185-92. PMID: 27157010.
      Citations:    Fields:    
    91. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15. PMID: 19332725; PMCID: PMC2739610.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    92. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, Harrell RK, Marom EM. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009 Mar; 50(3):340-7. PMID: 19258257.
      Citations: 62     Fields:    Translation:Humans
    93. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8. PMID: 19164229.
      Citations: 24     Fields:    Translation:Humans
    94. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging. 2009 Jun; 36(6):894-902. PMID: 19156410.
      Citations: 4     Fields:    Translation:Humans
    95. Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol. 2008 Nov; 191(5):1545-51. PMID: 18941099.
      Citations: 17     Fields:    Translation:Humans
    96. Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):890-9. PMID: 18514781; PMCID: PMC4103781.
      Citations: 9     Fields:    Translation:Humans
    97. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008 Sep; 142(5):786-92. PMID: 18564354.
      Citations: 10     Fields:    Translation:Humans
    98. Schwartz DL, Macapinlac HA, Weber RS. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment? J Natl Cancer Inst. 2008 May 21; 100(10):688-9. PMID: 18477798.
      Citations: 3     Fields:    Translation:Humans
    99. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr; 247(1):189-96. PMID: 18372468.
      Citations: 52     Fields:    Translation:Humans
    100. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med. 2008 Feb; 22(2):111-4. PMID: 18311535.
      Citations: 6     Fields:    Translation:Humans
    101. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med. 2008 Mar; 38(2):137-40. PMID: 18243849.
      Citations: 3     Fields:    Translation:Humans
    102. Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant. 2008 Apr; 14(4):478-80. PMID: 18342791.
      Citations: 5     Fields:    Translation:Humans
    103. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008 Feb; 46(1):23-9. PMID: 18297544.
      Citations: 19     Fields:    Translation:Humans
    104. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):435-40. PMID: 18164831; PMCID: PMC3385870.
      Citations: 9     Fields:    Translation:Humans
    105. Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging. 2007 Nov 26; 7:189-94. PMID: 18055293; PMCID: PMC2151325.
      Citations: 9     Fields:    Translation:Humans
    106. Macapinlac HA. Positron Emission Tomography of the Brain. PET Clin. 2007 Jan; 2(1):1-13. PMID: 27157702.
      Citations: 1     Fields:    
    107. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer. 2007 Nov 15; 110(10):2155-68. PMID: 17896784.
      Citations: 2     Fields:    Translation:Humans
    108. Namwongprom S, Yeung HW, Kim EE, Macapinlac HA, N??ez RF. Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes. 2007 Nov; 115(10):694-6. PMID: 18058606.
      Citations: 1     Fields:    Translation:Humans
    109. Yeung HW, Mehran RJ, Macapinlac HA, Cavalcanti JL, N??ez RF. Incidental finding of prostate cancer and adenomatous colon polyp in a patient with lung cancer. Clin Nucl Med. 2007 Nov; 32(11):871-3. PMID: 18075426.
      Citations:    Fields:    Translation:Humans
    110. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007 Nov-Dec; 27(6):1635-52. PMID: 18025508.
      Citations: 34     Fields:    Translation:Humans
    111. Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology. 2007 Dec; 245(3):692-702. PMID: 17911538.
      Citations: 37     Fields:    Translation:Humans
    112. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16. PMID: 17904303.
      Citations: 6     Fields:    Translation:Humans
    113. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008 Jun; 109(3):417-26. PMID: 17653852.
      Citations: 45     Fields:    Translation:Humans
    114. Podoloff DA, Macapinlac HA. PET and PET/CT in management of the lymphomas. Radiol Clin North Am. 2007 Jul; 45(4):689-96, vii. PMID: 17706533.
      Citations: 3     Fields:    Translation:Humans
    115. Yeung HW, Swanston NM, Macapinlac HA, N??ez R. [FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients]. Rev Esp Med Nucl. 2007 Jul-Aug; 26(4):234-6. PMID: 17662192.
      Citations:    Fields:    Translation:Humans
    116. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007 May 01; 25(13):1760-4. PMID: 17470866.
      Citations: 190     Fields:    Translation:Humans
    117. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007 May 01; 25(13):1753-9. PMID: 17470865.
      Citations: 480     Fields:    Translation:Humans
    118. Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol. 2007 Mar; 35(1):10-6; quiz 17-20. PMID: 17337652.
      Citations: 11     Fields:    Translation:Humans
    119. Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol. 2007 Jan-Feb; 36(1):21-9. PMID: 17198889.
      Citations: 9     Fields:    Translation:Humans
    120. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34. PMID: 17146785.
      Citations: 23     Fields:    Translation:Humans
    121. Namwongprom S, Kim EE, Macapinlac HA, N??ez R. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med. 2007 Jan; 32(1):35-8. PMID: 17179801.
      Citations: 5     Fields:    Translation:Humans
    122. Won KS, Gayed I, Kim EE, Macapinlac H. Juvenile fibroadenoma of the breast demonstrated on 111in-octreotide SPECT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2007 Mar; 34(3):440. PMID: 17119960.
      Citations: 1     Fields:    Translation:Humans
    123. Macapinlac HA. Positron emission tomography of the brain. Neuroimaging Clin N Am. 2006 Nov; 16(4):591-603, viii. PMID: 17148021.
      Citations: 1     Fields:    Translation:Humans
    124. Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer. 2006 Oct 15; 107(8):1898-908. PMID: 16986125.
      Citations: 14     Fields:    Translation:HumansCells
    125. Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys. 2006 Oct; 33(10):3931-8. PMID: 17089855.
      Citations: 34     Fields:    Translation:Humans
    126. Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol. 2006 Oct; 187(4):1116-23. PMID: 16985164.
      Citations: 6     Fields:    Translation:Humans
    127. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006 Aug; 47(8):1267-73. PMID: 16883004.
      Citations: 51     Fields:    Translation:Humans
    128. Marom EM, Munden RF, Truong MT, Gladish GW, Podoloff DA, Mawlawi O, Broemeling LD, Bruzzi JF, Macapinlac HA. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging. 2006 Aug; 21(3):205-12. PMID: 16915065.
      Citations: 11     Fields:    Translation:Humans
    129. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9. PMID: 16794124.
      Citations: 1     Fields:    Translation:Humans
    130. Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. PET Clin. 2006 Jul; 1(3):243-50. PMID: 27157363.
      Citations:    Fields:    
    131. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86. PMID: 17409902.
      Citations: 15     Fields:    Translation:Humans
    132. Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging. 2006 May; 21(2):137-45. PMID: 16770230.
      Citations: 10     Fields:    Translation:Humans
    133. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging. 2006 May; 21(2):99-110. PMID: 16770227.
      Citations: 5     Fields:    Translation:Humans
    134. Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, Kohlmyer S, Macapinlac HA, Podoloff DA. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol. 2006 May; 186(5):1458-67. PMID: 16632745.
      Citations: 12     Fields:    Translation:Humans
    135. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging. 2006 Mar; 50(1):61-7. PMID: 16557205.
      Citations: 4     Fields:    Translation:Humans
    136. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol. 2006 Feb; 186(2):308-19. PMID: 16423932.
      Citations: 31     Fields:    Translation:Humans
    137. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol. 2005 Dec 14; 11(46):7284-9. PMID: 16437629; PMCID: PMC4725130.
      Citations: 10     Fields:    Translation:Humans
    138. Macapinlac HA. FDG-PET in the evaluation of cervical cancer. Gynecol Oncol. 2005 Dec; 99(3 Suppl 1):S171-2. PMID: 16419203.
      Citations:    Fields:    Translation:Humans
    139. Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol. 2005 Oct; 2(10):526-33. PMID: 16205772.
      Citations: 7     Fields:    Translation:Humans
    140. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005 Sep; 46(9):1481-7. PMID: 16157531.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    141. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1406-11. PMID: 16133379.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    142. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005 Jul; 7(4):293-9. PMID: 15946589.
      Citations: 8     Fields:    Translation:Humans
    143. Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology. 2005 Jul; 236(1):271-5. PMID: 15987980.
      Citations: 15     Fields:    Translation:Humans
    144. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005 Jun; 129(6):1364-70. PMID: 15942579.
      Citations: 24     Fields:    Translation:Humans
    145. Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J. 2005 May; 28(5):284-95. PMID: 16086543.
      Citations: 2     Fields:    Translation:Humans
    146. Ramirez PT, Oh J, Viciedo MG, MacApinlac HA, Mart?nez-Rom?n S. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol. 2005 Mar; 96(3):888-91. PMID: 15721446.
      Citations:    Fields:    Translation:Humans
    147. Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, Sabloff BS, Bruzzi JF, Munden RF. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr. 2005 Mar-Apr; 29(2):205-9. PMID: 15772538.
      Citations: 5     Fields:    Translation:Humans
    148. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1136-43. PMID: 15718309.
      Citations: 81     Fields:    Translation:Humans
    149. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005 Jan-Feb; 25(1):191-207. PMID: 15653595.
      Citations: 28     Fields:    Translation:Humans
    150. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004 Dec; 183(6):1619-28. PMID: 15547201.
      Citations: 140     Fields:    Translation:HumansCTClinical Trials
    151. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
      Citations: 72     Fields:    Translation:Humans
    152. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60. PMID: 15464463.
      Citations: 83     Fields:    Translation:Humans
    153. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac H, National Electrical Manufacturers Association. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med. 2004 Oct; 45(10):1734-42. PMID: 15471842.
      Citations: 32     Fields:    Translation:Humans
    154. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 2004 Oct; 183(4):1127-32. PMID: 15385319.
      Citations: 50     Fields:    Translation:Humans
    155. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004 Sep 01; 64(17):5913-9. PMID: 15342366.
      Citations: 98     Fields:    Translation:HumansCells
    156. Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004 Jul-Aug; 10(4):262-70. PMID: 15383207.
      Citations: 5     Fields:    Translation:Humans
    157. Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol. 2004 Jul-Aug; 6(4):200-7. PMID: 15262235.
      Citations: 4     Fields:    Translation:Humans
    158. Truong MT, Erasmus JJ, Macapinlac HA, Podoloff DA. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol. 2004 Jun; 182(6):1587-9. PMID: 15150014.
      Citations: 2     Fields:    Translation:Humans
    159. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004 Jan; 45(1):17-21. PMID: 14734662.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    160. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW, American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1943-51. PMID: 14688710.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    161. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003 Sep; 44(9):1407-12. PMID: 12960184.
      Citations: 37     Fields:    Translation:Humans
    162. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol. 2003 Jan-Feb; 5(1):26-31. PMID: 14499159.
      Citations: 5     Fields:    Translation:Humans
    163. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002 Jul; 43(7):876-81. PMID: 12097456.
      Citations: 109     Fields:    Translation:Humans
    164. Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med. 2002 Jun; 46(2):122-30. PMID: 12114875.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    165. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002 Jun; 59(6):913-8. PMID: 12031380.
      Citations: 64     Fields:    Translation:Humans
    166. Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM, Nu?ez R. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002 Jan; 43(1):46-55. PMID: 11801702.
      Citations: 43     Fields:    Translation:Humans
    167. Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging. 2002 Jan; 29(1):61-6. PMID: 11807608.
      Citations: 12     Fields:    Translation:Humans
    168. Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med. 2001 Sep; 45(3):235-44. PMID: 11788816.
      Citations: 8     Fields:    Translation:Humans
    169. Turlakow A, Yeung HW, Pui J, Macapinlac H, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med. 2001 Apr 09; 161(7):1003-7. PMID: 11295964.
      Citations: 17     Fields:    Translation:Humans
    170. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med. 2001 Mar; 26(3):193-7. PMID: 11245108.
      Citations: 4     Fields:    Translation:Humans
    171. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001 Feb; 28(2):155-64. PMID: 11303885.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    172. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract. 2000 Nov-Dec; 6(6):460-4. PMID: 11155220.
      Citations: 10     Fields:    Translation:Humans
    173. Yeung HW, Macapinlac HA, Castro-Malaspina H, Larson SM, Nu?ez RF. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med. 2000 Sep; 25(9):676-8. PMID: 10983752.
      Citations:    Fields:    Translation:Humans
    174. Chisin R, Macapinlac HA. The indications of FDG-PET in neck oncology. Radiol Clin North Am. 2000 Sep; 38(5):999-1012. PMID: 11054965.
      Citations: 2     Fields:    Translation:Humans
    175. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000 Jul; 27(7):861-6. PMID: 10952499.
      Citations: 30     Fields:    Translation:Humans
    176. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000 Mar; 85(3):1107-13. PMID: 10720047.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    177. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000 Mar; 18(6):1173-80. PMID: 10715285.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    178. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid. 2000 Feb; 10(2):177-83. PMID: 10718556.
      Citations: 8     Fields:    Translation:Humans
    179. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan; 43(1):18-24. PMID: 10813118.
      Citations: 33     Fields:    Translation:HumansCells
    180. Macapinlac HA, Yeung HW, Larson SM. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging. 1999 Nov; 2(6):311-316. PMID: 14516613.
      Citations:    
    181. Rini JN, Yeung HW, Nunez RF, la Calle JP, Larson S, Macapinlac HA. FDG-PET Patterns of Abdominal Carcinomatosis. Clin Positron Imaging. 1999 Nov; 2(6):333. PMID: 14516630.
      Citations: 1     
    182. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging. 1999 Oct; 2(5):255-260. PMID: 14516649.
      Citations: 7     
    183. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999 Oct; 178(4):282-7. PMID: 10587184.
      Citations: 47     Fields:    Translation:Humans
    184. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999 Jul; 84(7):2291-302. PMID: 10404792.
      Citations: 51     Fields:    Translation:Humans
    185. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 1999 May; 2(3):159-171. PMID: 14516540.
      Citations: 211     
    186. Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin Positron Imaging. 1999 May; 2(3):173-181. PMID: 14516541.
      Citations: 10     
    187. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med. 1999 Apr; 24(4):281-2. PMID: 10466532.
      Citations: 1     Fields:    Translation:Humans
    188. Erdi YE, Macapinlac H, Larson SM, Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging. 1999 Jan; 2(1):41-46. PMID: 14516552.
      Citations: 25     
    189. Yeung HW, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging. 1998 Sep; 1(4):213-221. PMID: 14516555.
      Citations: 23     
    190. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract. 1998 Sep-Oct; 4(5):282-6. PMID: 15251726.
      Citations: 7     Fields:    
    191. Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1177-83. PMID: 9719130.
      Citations: 1     Fields:    Translation:Humans
    192. Akhurst T, Boland P, Macapinlac H, Finn R, Yeung HW, Squire O, Larson SM. Excess Muscle FDG Uptake in an Euglycaemic Patient That Is Corrected by Fasting. Clin Positron Imaging. 1998 Mar; 1(2):131-133. PMID: 14516602.
      Citations:    
    193. Macapinlac HA, Larson SM. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am. 1997 Nov-Dec; 3(6):333-5. PMID: 9403044.
      Citations:    Fields:    Translation:Humans
    194. el-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med. 1997 Aug; 38(8):1208-10. PMID: 9255151.
      Citations: 9     Fields:    Translation:Humans
    195. Yeung H, Macapinlac H. First impressions. A 21-yr-old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings? J Nucl Med. 1996 Dec; 37(12):7A, 1994. PMID: 8999117.
      Citations:    Fields:    Translation:Humans
    196. Yeung HW, Imbriaco M, Zhang JJ, Macapinlac H, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med. 1996 Sep; 37(9):1528-30. PMID: 8790210.
      Citations: 6     Fields:    Translation:Humans
    197. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N, Larson SM. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med. 1996 Apr; 37(4 Suppl):29S-32S. PMID: 8676201.
      Citations: 3     Fields:    Translation:Humans
    198. Macapinlac HA, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, Larson SM. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med. 1996 Apr; 37(4 Suppl):25S-29S. PMID: 8676200.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    199. Reinsel RA, Veselis RA, Feshchenko VA, Di Resta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg R, Macapinlac H, et al. Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Ann N Y Acad Sci. 1995 Dec 15; 769:393-7. PMID: 8595041.
      Citations: 2     Fields:    Translation:Humans
    200. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin-receptor imaging in lymphoma. Semin Nucl Med. 1995 Jul; 25(3):262-71. PMID: 7570045.
      Citations: 6     Fields:    Translation:Humans
    201. Abdel-Dayem H, Bag R, Macapinlac H, Elgazzar AH, Habbab N, Pescatore F, Kempf J. Diffuse Tl-201 uptake in the lungs. Etiologic classification and pattern recognition. Clin Nucl Med. 1995 Feb; 20(2):164-72. PMID: 7720309.
      Citations: 2     Fields:    Translation:Humans
    202. Scott AM, Macapinlac H, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SD, et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med. 1995 Jan; 36(1):100-3. PMID: 7799059.
      Citations: 6     Fields:    Translation:Humans
    203. Caluser C, Scott A, Macapinlac H, Yeh S, Rosenfelt N, Farid B, Abdel-Dayem HM, Larson SM, Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med. 1995 Jan; 20(1):75. PMID: 7895447.
      Citations: 1     Fields:    Translation:Humans
    204. Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med. 1994 Dec; 35(12):1976-84. PMID: 7989980.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    205. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, Kalaigian H, Yeh SD, Larson SM. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med. 1994 Nov; 21(11):1198-205. PMID: 7859771.
      Citations: 7     Fields:    Translation:Humans
    206. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994 Nov; 35(11):1748-52. PMID: 7525900.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    207. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med. 1994 Sep; 35(9):1407-17. PMID: 8071684.
      Citations: 7     Fields:    Translation:Humans
    208. Larson SM, Divgi C, Scott A, Daghighian F, Macapinlac H, Welt S. Current status of radioimmunodetection. Nucl Med Biol. 1994 Jul; 21(5):721-9. PMID: 9241648.
      Citations:    Fields:    Translation:Humans
    209. Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol. 1994 Jul; 21(5):731-8. PMID: 9241649.
      Citations: 1     Fields:    Translation:Humans
    210. Scott AM, Macapinlac H, Zhang JJ, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. Nucl Med Biol. 1994 Jul; 21(5):775-84. PMID: 9241654.
      Citations: 6     Fields:    Translation:Humans
    211. Abdel-Dayem HM, Scott A, Macapinlac H, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med. 1994 Jan; 21(1):57-81. PMID: 8088287.
      Citations: 13     Fields:    Translation:Humans
    212. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med. 1993 Sep; 18(9):751-3. PMID: 8403716.
      Citations: 4     Fields:    Translation:Humans
    213. Rusch V, Macapinlac H, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993 Aug; 106(2):200-4. PMID: 8393504.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    214. Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac H, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993 May; 20(5):402-9. PMID: 8519259.
      Citations: 15     Fields:    Translation:Humans
    215. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol. 1993; 32(7-8):709-15. PMID: 8305216.
      Citations: 1     Fields:    Translation:Humans
    216. Caluser C, Healey J, Macapinlac H, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Tl-201 uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone imaging. Clin Nucl Med. 1992 Sep; 17(9):751-3. PMID: 1395357.
      Citations: 5     Fields:    Translation:Humans
    217. Roistacher N, Preminger M, Macapinlac H, Pierri MK. Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. Am Heart J. 1992 Aug; 124(2):516-21. PMID: 1636600.
      Citations:    Fields:    Translation:Humans
    218. Caluser C, Macapinlac H, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med. 1992 Jul; 17(7):565-72. PMID: 1638838.
      Citations: 10     Fields:    Translation:Humans
    219. Hoener B, Engelstad BL, Ramos EC, Macapinlac HA, Price DC, Johnson TR, White DL. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging. 1991 May-Jun; 1(3):357-62. PMID: 1802149.
      Citations: 5     Fields:    Translation:Animals
    220. Accuracy of FDG-PET in gastric cancer. Clinical Positron Imaging (Netherlands). 1:213-221.
    221. Differential metabolism and pharmacokinetics of L-[1-11C]-methionine and 2-[18F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer. Clinical Positron Imaging (Netherlands). 2:173-181.
    222. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology. 21:33-39.
    223. PET Imaging of Prostate Cancer. PET Clinics. 4:185-192.
    224. The role of 18F-FDG PET/CT in diagnosis and staging of musculoskeletal soft tissue sarcomas. Clinical and Translational Imaging. 3:111-121.
    225. Diffuse large B-Cell lymphoma. Radiology. 280:220-229.
    226. Reply. Journal of Nuclear Medicine. 57:991.
    227. Assessing response to therapy. 25-33.
    228. FDG-PET in esophageal cancer. Clinical Positron Imaging (Netherlands). 2:255-260.
    229. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clinical Positron Imaging (Netherlands). 2:159-171.
    230. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clinical Positron Imaging (Netherlands). 3:107-114.
    231. Factors affecting quantification in PET/CT imaging. Current Medical Imaging Reviews. 4:34-45.
    232. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clinical Positron Imaging (Netherlands). 2:41-46.
    233. Positron Emission Tomography of the Brain. PET Clinics. 2:1-13.
    234. Qualitative and quantitative comparison of gated blood pool single photon emission computed tomography using low-energy high-resolution and SMARTZOOM collimation. Nuclear Medicine Communications. 38:35-43.
    235. Tracer imaging in lung cancer. European Journal Of Nuclear Medicine. 22:1355.
    236. Carcinoid tumor of the kidney. Urologic Oncology. 5:108-111.
    237. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. International Braz J Urol. 34:778.
    238. Defining the role of FDG PET in head and neck cancer. Clinical Positron Imaging (Netherlands). 2:311-316.
    239. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging. 1-10.
    240. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. Journal of Applied Clinical Medical Physics. 11:217-228.
    241. Skeletal tumor burden on baseline 18F-fluoride PET/CT predicts bone marrow failure after 223Ra therapy. Clinical Nuclear Medicine. 41:268-273.
    242. Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies. European Journal of Nuclear Medicine and Molecular Imaging. 1-11.
    243. Colorectal carcinoma. 108-123.
    244. Excess muscle FDG uptake in an euglycaemic patient that is corrected by fasting. Clinical Positron Imaging (Netherlands). 1:131-133.
    245. PET and PET/CT in Management of the Lymphomas. PET Clinics. 1:243-250.
    246. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
    247. Erratum. European Journal Of Nuclear Medicine. 22:1355.
    MACAPINLAC's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (503)
    Explore
    _
    Co-Authors (174)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _